Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MST1R pos PIK3CA wild-type |
| Therapy | Buparlisib |
| Indication/Tumor Type | estrogen-receptor positive breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R pos PIK3CA wild-type | estrogen-receptor positive breast cancer | predicted - sensitive | Buparlisib | Preclinical - Pdx | Actionable | In a preclinical study, BKM120 inhibited tumor growth in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer with wild-type PIK3CA and expressing the short isoform of MST1R (RON) (PMID: 26289070). | 26289070 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26289070) | Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. | Full reference... |